Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Jasper Therapeutics Q2 EPS $(0.29)

Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(0.29) per share.

byMichael Horton

August 12, 2022

1 minute read

Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(0.29) per share.

General
News

Tyson Foods Employees From Chicago And Dakota Business Units Plan To Quit

By Shivani Kumaresan

Today, 12:06 PM

Tyson Foods Inc (NYSE: TSN) employees from its Illinois and South Dakota business units are planning to leave the company.

TSN

Moonlake Immunotherapeutics To Initiate Global Phase 2 Study Of The Nanobody Sonelokimab In Patients With Active Psoriatic Arthritis

By Bill Haddad

Today, 12:06 PM

MoonLake announces FDA clearance for Phase 2 clinical study of the Nanobody® sonelokimab in active psoriatic arthritis Expected to enroll approximately 200 patients to assess the efficacy and safety of sonelokimab

MLTX

Needham Maintains Buy on Pros Holdings, Lowers Price Target to $35

By Benzinga Newsdesk

Today, 12:06 PM

Needham analyst Scott Berg maintains Pros Holdings (NYSE:PRO) with a Buy and lowers the price target from $51 to $35.

PRO

Keybanc Initiates Coverage On Brilliant Earth Group with Overweight Rating, Announces Price Target of $16

By Benzinga Newsdesk

Today, 12:06 PM

Keybanc analyst Edward Yruma initiates coverage on Brilliant Earth Group (NASDAQ:BRLT) with a Overweight rating and announces Price Target of $16.

BRLT

Jasper Therapeutics Q2 EPS $(0.29)

Related Posts

Tyson Foods Employees From Chicago And Dakota Business Units Plan To Quit

Moonlake Immunotherapeutics To Initiate Global Phase 2 Study Of The Nanobody Sonelokimab In Patients With Active Psoriatic Arthritis

Needham Maintains Buy on Pros Holdings, Lowers Price Target to $35

Keybanc Initiates Coverage On Brilliant Earth Group with Overweight Rating, Announces Price Target of $16